Loading clinical trials...
Loading clinical trials...
A PHASE 3, RANDOMIZED OBSERVER-BLINDED STUDY TO EVALUATE THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER
Conditions
Interventions
Clostridium difficile
Placebo
Locations
52
United States
North Alabama Research Center, LLC
Athens, Alabama, United States
Medical Affiliated Research Center
Huntsville, Alabama, United States
East Valley Gastroenterology and Hepatology Associates
Chandler, Arizona, United States
The Pain Center of Arizona
Peoria, Arizona, United States
HOPE Research Institute
Phoenix, Arizona, United States
The Pain Center of Arizona
Phoenix, Arizona, United States
Start Date
April 1, 2019
Primary Completion Date
December 22, 2020
Completion Date
December 22, 2020
Last Updated
January 10, 2024
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions